• Gossamer Bio Inc GOSS.OQ reported a quarterly adjusted loss of 14 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -21 cents. The mean expectation of ten analysts for the quarter was for a loss of 15 cents per share. Wall Street expected results to range from -22 cents to -1 cents per share.

• Revenue was $9.48 million​; analysts expected $7.70 million.

• Gossamer Bio Inc's reported EPS for the quarter was a loss of 14 cents​.

• The company reported a quarterly loss of $30.8 million.

• Gossamer Bio Inc shares had fallen by 10.1% this quarter and lost 2.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 22.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Gossamer Bio Inc is 7.00

This summary was machine generated from LSEG data November 8 at 04:45 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)